GEM 91 genetic antisense compound targeted to products of the HIV-1 gag gene data

HYBN unblinded results of the three highest dose levels of its Phase Ib/II trial. The study tested decreases

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE